InvestSMART

Healius Limited (ASX:HLS)

ALERT: Price-sensitive ASX Announcement for HLS
Current share price for HLS : $0.455 0.09 (24.66%)+
Announcement
Release
26 Jun 2026 5:09PM
Price at Release
$0.365
Full Release
download
Summary
Healius Limited has announced a new national agreement framework with the wholly-owned subsidiaries of Ramsay Health Care Limited, transitioning its existing pathology service arrangements into a uniform set of agreements effective from July 1, 2026. This strategic move covers Healius' operations across thirteen Ramsay-operated hospitals in New South Wales, Western Australia, Victoria, and Queensland. The new agreements have initial terms ranging from two to five years, with an expected annual revenue of approximately $45 million, assuming consistent customer demand and stable economic conditions. Healius CEO Paul Anderson expressed satisfaction with the extended collaboration, emphasizing the continuation of quality pathology services. The announcement also highlighted the scope and footprint of Healius' services in Australia, underscoring its commitment to affordable and accessible healthcare.
Key Points
  • Healius Limited enters national agreement framework with Ramsay subsidiaries.
  • The agreement takes effect on July 1, 2026, covering 13 Ramsay hospitals.
  • No change to existing pathology services, but transitions to uniform agreements.
  • Initial agreement terms range from two to five years.
  • Expected annual revenue of approximately $45 million.
  • Healius continues as the provider for both public and private patients.
  • CEO Paul Anderson highlights commitment to quality and consistency.
  • Healius has a significant healthcare footprint in Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.